Balaxi Pharmaceuticals Ltd (NSE: BALAXI) is a Hyderabad, Telangana-based company in the Health Care Distributors industry. With a market capitalisation of ₹125 Cr, it ranks #3,056 by market cap among the 6,197 Indian listed companies on FinBizNet, and #4 of 11 in Health Care Distributors. At ₹23.50 (as of 16 Nov 2026), the share price is 42.7% below its 52-week high of ₹40.98 and 54.6% above its 52-week low of ₹15.20. The share price is down 44.5% over one year and down 2.3% over three months.
| Current Price | ₹23.50 |
|---|---|
| Market Cap | ₹125 Cr |
| NSE Symbol | BALAXI |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Distributors |
| P/E Ratio | 92.2 |
| Return on Equity | 0.59% |
| Return on Assets | 1.23% |
| 52-Week Range | ₹15.20 – ₹40.98 |
| 1-Year Price Change | -44.5% |
| 3-Month Price Change | -2.3% |
| Beta (1Y) | 0.61 |
| Dividend Yield | 0.00% |
| Headquarters | Hyderabad, Telangana |
| Website | balaxipharma.in |
| Revenue | ₹81 Cr |
|---|---|
| Net Profit | ₹1 Cr |
| Net Margin | 1.4% |
| EPS (Basic) | ₹0.21 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Balaxi Pharmaceuticals Ltd reported revenue of ₹81 Cr in Q2 FY27, up 44.8% from ₹56 Cr in Q2 FY26 and up 0.9% from ₹81 Cr in Q1 FY27. It posted a net profit of ₹1 Cr for the quarter, against a net profit of ₹0 Cr in Q2 FY26 (up 447.6%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹56 Cr (Q2 FY26) to ₹81 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹81 Cr | ₹1 Cr | 1.4% |
| Q1 FY27 | ₹81 Cr | ₹1 Cr | 1.6% |
| Q4 FY26 | ₹71 Cr | ₹1 Cr | 0.9% |
| Q3 FY26 | ₹73 Cr | ₹0 Cr | 0.4% |
| Q2 FY26 | ₹56 Cr | ₹0 Cr | 0.4% |
| Q1 FY26 | ₹71 Cr | ₹0 Cr | 0.4% |
| Q4 FY25 | ₹76 Cr | ₹9 Cr | 11.3% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 65.99% of Balaxi Pharmaceuticals Ltd's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 80.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in India, Africa, and Latin America. The company offers pharmaceutical products across various therapeutic areas, including antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpaste. The company was formerly known as Balaxi Ventures Limited and changed its name to Balaxi Pharmaceuticals Limited in October 2020. The company was incorporated in 1942 and is headquartered in Hyderabad, India. Balaxi Pharmaceuticals Limited is a subsidiary of Balaxi Overseas Private Limited.
1. Specialized Wholesale-This segment engages in providing investment services.
1. Specialized Wholesale-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Trimurthi Ltd | ₹197 Cr | 57.6 | 7.99% | — | +33.3% |
| Achyut Healthcare Ltd | ₹191 Cr | 609.2 | 0.95% | — | +39.7% |
| Vaidya Sane Ayurved Laboratories | ₹148 Cr | — | 13.40% | — | -46.6% |
| Balaxi Pharmaceuticals Ltd | ₹125 Cr | 92.2 | 0.59% | ₹81 Cr | -44.5% |
| Medico Intercontinental Ltd | ₹25 Cr | n/m | -27.14% | ₹14 Cr | -31.5% |
| Zenlabs Ethica Ltd | ₹19 Cr | n/m | -20.44% | — | -12.5% |
| Rubra Medicaments Ltd. | ₹18 Cr | 12.2 | 12.67% | — | -53.2% |
| Nexus Surgical & Medicare Ltd | ₹15 Cr | 20 | 51.41% | — | +76.5% |
| Brawn Biotech Ltd. | ₹7 Cr | 7 | 24.43% | — | +9.4% |
Listed by market capitalisation. Ratios are shown for context only.
Balaxi Pharmaceuticals Ltd is trading at ₹23.50, with a market capitalisation of ₹125 Cr.
Balaxi Pharmaceuticals Ltd operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Distributors).
Balaxi Pharmaceuticals Ltd has a P/E of 92.2 and a return on equity of 0.59%.
Balaxi Pharmaceuticals Ltd is listed on the NSE under the symbol BALAXI.
Balaxi Pharmaceuticals Ltd's share price is down 44.5% over one year and down 2.3% over three months. Its 52-week range is ₹15.20 to ₹40.98.
In Q2 FY27, Balaxi Pharmaceuticals Ltd reported revenue of ₹81 Cr and net profit of ₹1 Cr, with basic EPS of ₹0.21 (consolidated, parsed from the company's exchange filing).
Balaxi Pharmaceuticals Ltd reported revenue of ₹81 Cr in Q2 FY27, up 44.8% from ₹56 Cr in Q2 FY26 and up 0.9% from ₹81 Cr in Q1 FY27.
Promoters held 65.99% of Balaxi Pharmaceuticals Ltd's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.